Comparing EGFR Measurement Techniques in Lung Cancer
Author Information
Author(s): P Pfeiffer, E Nexø, SM Bentzen, PP Clausen, K Andersen, C Rose
Primary Institution: Odense University Hospital, Denmark
Hypothesis
The study aims to compare the quantification of epidermal growth factor receptor (EGFR) using enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) in lung cancer patients.
Conclusion
The study concludes that both IHC and ELISA provide comparable results for measuring EGFR in lung cancer, particularly when IHC is assessed with a scoring system.
Supporting Evidence
- The correlation between EGFR levels measured by ELISA and IHC was highly significant (r = 0.63, p < 0.001).
- EGFR expression was highest in squamous cell carcinomas.
- EGFR levels were not correlated with age, sex, histological grading, stage, or prognosis.
Takeaway
Scientists looked at how to measure a protein called EGFR in lung cancer patients using two different methods and found that both methods give similar results.
Methodology
The study used fresh-frozen tissue from 190 lung cancer patients to compare EGFR levels measured by ELISA and IHC.
Limitations
The study did not find a correlation between EGFR expression and survival in lung cancer patients.
Participant Demographics
Median age of participants was 61 years, with 131 men and 59 women.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 2.2-7.7
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website